Funding cuts to medical research pose a significant threat to the ongoing efforts aimed at ensuring patient safety and ethical oversight in clinical trials.As federal grants shrink, vital resources that support Institutional Review Boards (IRBs) and regulatory frameworks are severely compromised, leading to potential risks for research participants.